Biogen Idec Inc. is targeting a yet-untreated disease that affects 150,000 Americans while seeking to expand its business of producing drugs for neurological disorders through a deal with a young Cambridge startup.
Cambridge-based Biogen today said it has backed Ataxion, a startup founded a year ago by Cambridge venture capital firm Atlas Venture. Both Biogen and Atlas took part in a $17 million funding deal for the startup, which could also see Ataxion acquired by Biogen if certain milestones are achieved.
Get BetaBoston by Email
Make BetaBoston yours
Add tags to My Beta to follow the news stories, trends, and companies you care about.